NCT03018054CompletedPhase 2
A Phase 2, Double-Blind, Parallel-Group, Placebo-Controlled Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- EA Pharma Co., Ltd.
- Enrollment
- 147
- Locations
- 3
- Primary Endpoint
- Change from Baseline in Mayo score at 8 weeks
Study Overview
Brief Summary
This is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of E6007 once daily for 8 weeks in Japanese participants with moderate active ulcerative colitis. Participants will be stratified by prior therapeutic treatment and Mayo score at Baseline, and will be randomized 1:1:1 to receive E6007 30 milligrams (mg), E6007 60 mg or placebo.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 20 Years to 74 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Japanese participants aged from 20 to 74 years at the time of informed consent
- •Participants with a diagnosis based on the Revised Diagnostic Criteria for Ulcerative Colitis (UC) issued by the Research Group for Intractable Inflammatory Bowel Disease Designated as Specified Disease by the Ministry of Health, Labor and Welfare of Japan (2013) at least 4 weeks before the start of administration of study drug
- •Active UC participants as determined by Baseline complete Mayo score of 6 to 10 points with an endoscopic subscore of ≥2 and a rectal bleeding subscore of ≥1
- •Participants who are currently being treated with oral 5-ASA or immunomodulator or corticosteroid with inadequate response or intolerance, or are corticosteroid dependent
- •Participants being seen on an outpatient basis
- •Has voluntarily consented, in writing, to participate in this study and is able and willing to comply with the requirements of this study protocol
Exclusion Criteria
- •Reduction in partial Mayo score of ≥3 points at Baseline from Screening
- •Diagnosed with right-sided or segmental colitis, and proctitis from a Baseline endoscopy
- •Received any anti-tumor necrosis factor (TNF) agent for over 2 years, or within 12 weeks prior to Baseline
- •History of colectomy, or planning to have surgery for treatment of UC at Screening or Baseline
- •White blood cell count below 3000/microliters (µL) at Screening
- •History or suspected history of central nervous system disorder found at Screening or Baseline
- •Current complication or suspected malignancy or toxic megacolon at Screening or Baseline
- •Prior history or current complication of colonic dysplasia at Screening or Baseline
- •History of any severe drug allergy at Screening or Baseline
- •Received a live vaccine within 4 weeks prior to Baseline
- •QTc repeatedly above 450 milliseconds (ms) on the electrocardiogram (ECG) test at Screening
- •In the case of women: nursing mothers or pregnant women at Screening or Baseline
- •Refusal to use medically suitable contraception (both the participant and the participant's partner) throughout the entire study period, if the participant is a man capable of reproduction or a woman of childbearing potential
- •Female participants who want to become pregnant or male participants whose partners want to become pregnant throughout the entire study period
- •Evidence of clinically significant disease that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments at Screening or Baseline
- •History of any medical conditions or concomitant medical conditions that in the opinion of the investigator(s) would compromise the participant's ability to safely complete the study at Screening or Baseline
- •A positive finding on the human immunodeficiency virus antigen and antibody test at Screening
- •In tests conducted at Screening, a positive finding for any of the following: hepatitis B virus surface antigen, hepatitis B virus surface antibody, hepatitis B virus core antibody, or hepatitis C virus antibody
- •Any result other than negative on the tuberculosis test at Screening
- •Findings indicating a history of tuberculosis on chest X-ray during Screening
- •History of drug or alcohol dependency or abuse within approximately the last 2 years prior to Screening or Baseline
- •Use of illegal recreational drugs at Screening or Baseline
- •Currently enrolled in another clinical trial or used any investigational drug or device within 16 weeks preceding informed consent
Arms & Interventions
E6007 60 mg
Experimental
Participants will receive E6007 60 mg once daily after breakfast.
Intervention: E6007 (Drug)
Placebo
Placebo Comparator
Participants will receive matching placebo once daily after breakfast.
Intervention: Placebo (Drug)
E6007 30 mg
Experimental
Participants will receive E6007 30 milligrams (mg) once daily after breakfast.
Intervention: E6007 (Drug)
Outcomes
Primary Outcomes
Change from Baseline in Mayo score at 8 weeks
Time Frame: Baseline; 8 weeks
Secondary Outcomes
- Number of participants with abnormal, clinically significant laboratory values(up to 8 weeks)
- Change from Baseline in heart rate at 8 weeks(Baseline; 8 weeks)
- Change from Baseline in standard 12-lead electrocardiogram (ECG) values(Baseline; 8 weeks)
- Change from Baseline in body temperature at 8 weeks(Baseline; 8 weeks)
- Change from Baseline in respiratory rate at 8 weeks(Baseline; 8 weeks)
- Number of participants with abnormal, clinically significant chest X-ray findings(up to 8 weeks)
- Number of participants with any serious adverse event and number of participants with any non-serious adverse event(up to 8 weeks)
- Change from Baseline in diastolic blood pressure and systolic blood pressure at 8 weeks(Baseline; 8 weeks)
Investigators
Study Sites (3)
Loading locations...
Similar Trials
Completed
Phase 2
Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisCystic FibrosisNCT03451045Corbus Pharmaceuticals Inc.447
Completed
Phase 2
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)Raynaud Phenomenon Secondary to Systemic SclerosisNCT03867097Civi Biopharma, Inc.34
Not yet recruiting
Phase 2
A Study of HS-10353 in Adult Participants With Major Depressive DisorderMajor Depressive Disorder (MDD)NCT05938179Jiangsu Hansoh Pharmaceutical Co., Ltd.144
Withdrawn
Phase 2
Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Knee Replacement in Patients With High PCS ScoresPain, PostoperativeNCT03797612Adynxx, Inc.
Completed
Phase 2
Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)Childhood-Onset Fluency Disorder (Stuttering)NCT04492956Emalex Biosciences Inc.68